← UNITED THERAPEUTICS Corp
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | $713.7m | $417.9m | $589.2m | ($104.5m) | $514.8m | $475.8m | $727.3m | $984.8m | $1.2b | $1.3b | — | |
| Depreciation, Depletion and Amortization | $31.6m | $31.0m | $35.9m | $45.9m | $49.9m | $49.9m | $51.3m | $53.2m | $72.5m | $85.6m | $91.5m | |
| Depreciation | $31.0m | $30.5m | $35.8m | $45.7m | $49.7m | $49.8m | $51.2m | $52.9m | $71.6m | $84.7m | $84.7m | |
| Amortization of Intangible Assets | $600k | $500k | $100k | $200k | $200k | $100k | $100k | $300k | $900k | $900k | — | |
| Deferred Income Tax Expense (Benefit) | $10.5m | $66.4m | $15.7m | ($133.0m) | ($10.5m) | ($18.8m) | ($50.8m) | ($64.4m) | ($64.1m) | $97.7m | $149.3m | |
| Share-based Payment Arrangement, Noncash Expense | $12.1m | $73.5m | ($26.4m) | $45.4m | $163.8m | $138.5m | $106.8m | $39.1m | $144.0m | $147.7m | $155.4m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | $2.1m | $3.7m | $10.8m | $11.4m | $13.8m | $12.2m | $16.6m | — | |
| Share-based Payment Arrangement, Expense | — | $73.5m | ($26.4m) | $45.4m | $163.8m | $138.5m | $106.8m | $39.1m | $144.0m | $147.7m | $155.4m | |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount | — | — | — | — | — | $2.3m | $1.7m | $0 | $0 | — | — | |
| Goodwill, Impairment Loss | $0 | $0 | $0 | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Impairment of Intangible Assets, Finite-lived | $0 | $0 | $0 | — | — | $0 | $0 | $0 | $0 | $0 | — | |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) | $0 | $0 | $0 | $0 | $0 | $113.4m | $0 | $0 | $0 | $0 | — | |
| Nonoperating Income (Expense) | ($1.5m) | ($45.4m) | ($46.5m) | $22.6m | $45.3m | $38.0m | ($29.1m) | $89.4m | $162.0m | $221.4m | — | |
| Other Nonoperating Income (Expense) | $2.4m | $13.2m | ($7.7m) | $22.6m | $49.3m | $42.2m | ($40.2m) | ($14.0m) | $5.8m | $48.9m | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | $21.7m | $82.7m | ($121.4m) | ($24.4m) | $6.0m | $41.3m | $21.7m | $58.5m | $400k | $70.9m | $69.0m | |
| Increase (Decrease) in Inventories | $24.5m | $500k | ($9.3m) | ($12.9m) | ($10.3m) | $7.5m | $13.4m | $13.6m | $46.9m | $52.6m | ($91.8m) | |
| Net Cash Provided by (Used in) Operating Activities | $643.6m |
$474.2m
-26.32%
|
$778.4m
+64.15%
|
($206.6m)
-126.54%
|
$755.7m
+465.78%
|
$598.2m
-20.84%
|
$802.5m
+34.15%
|
$978.0m
+21.87%
|
$1.3b
+35.70%
|
$1.6b
+17.64%
|
$1.7b
+7.94%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $38.0m | $86.3m | $184.4m | $83.7m | $59.3m | $120.8m | $138.8m | $230.4m | $246.5m | $520.5m | ($597.7m) | |
| Payments to Acquire Investments | $36.0m | — | — | — | — | — | — | — | — | — | ($1.7b) | |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale | — | $20.0m | $265.9m | $799.2m | $1.5b | $1.4b | $1.0b | $2.1b | $1.5b | $1.6b | — | |
| Payments to Acquire Businesses, Net of Cash Acquired | — | — | $124.1m | — | $0 | — | — | $89.2m | $0 | $0 | ($80.0m) | |
| Net Cash Provided by (Used in) Investing Activities | $48.3m | ($835.6m) | ($820.6m) | ($335.4m) | ($738.5m) | ($486.9m) | ($811.5m) | ($719.6m) | $417.2m | ($551.3m) | $744.5m | |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common Stock | $500.0m | $250.0m | — | — | — | — | $0 | $0 | $1.0b | $1.0b | — | |
| Net Cash Provided by (Used in) Financing Activities | ($497.7m) |
$43.3m
+108.70%
|
$6.3m
-85.45%
|
$611.2m
+9601.59%
|
($16.9m)
-102.77%
|
$44.8m
+365.09%
|
$75.4m
+68.30%
|
($11.9m)
-115.78%
|
($1.3b)
-10444.54%
|
($1.1b)
+8.35%
|
($2.2b)
-93.01%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $191.2m | ($317.9m) | ($35.9m) | $69.2m | $300k | $156.1m | $66.4m | $246.5m | $489.5m | ($140.1m) | $1.8b | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | $738.7m | $894.8m | $961.2m | $1.2b | $1.7b | $1.6b | $1.8b | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | $7.7m | $39.9m | $15.6m | $9.9m | $33.8m | $50.0m | $88.4m | $98.0m | $152.5m | $173.9m | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | $1.5m | $7.5m | $9.4m | $41.0m | $20.7m | $16.2m | $29.1m | $56.0m | $40.2m | $13.5m | — | |
| Income Taxes Paid, Net | $362.4m | $346.9m | $102.7m | $120.2m | $92.8m | $153.3m | $275.7m | $332.5m | $400.6m | $313.3m | — | |
| Additional Financial Items | ||||||||||||
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement | — | — | — | — | — | $0 | — | $1.8m | $0 | $600k | — | |
| Goodwill | $10.3m | $13.7m | $31.5m | $28.0m | $28.0m | $28.0m | $28.0m | $33.7m | $32.3m | $32.3m | $0 | |
| Income Tax Expense (Benefit) | $346.5m | $351.6m | $169.7m | ($60.5m) | $124.1m | $118.1m | $223.3m | $289.5m | $343.9m | $379.2m | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $42.9m | $19.5m | — | |
| Investment Income, Interest | — | — | $28.6m | $44.2m | $28.6m | $16.7m | $45.2m | $162.7m | $199.1m | $192.0m | — | |
| Operating Lease, Expense | — | — | — | — | $3.5m | $3.6m | $4.8m | — | — | — | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.